Abstract:e20506 Background: Cancervaccines have become one of the hot areas of research in recent years. However, different types of tumors and the tumor tissue itself are heterogeneous. Some cancervaccines contain a single epitope and have weak immunogenicity. The antigen-presenting cells cannot adequately absorb and present the antigen peptide contained in the vaccine. As a result, the body fails to elicit an effective immune response, which greatly limits the therapeutic effect of the cancervaccine. In situ cancervaccines composed of antigens and adjuvants are a promising cancer treatment modality; however, convenient manufacturing of vaccines in vivo and their efficient delivery to lymph nodes (LNs) remain a significant challenge. In this study, we outline a facile approach to simultaneously achieve in situ programming of vaccines via two synergistic nanomedicines to generate robust immune responses. Methods: We first prepared two synergistic nanocomposite systems: Gold nanorods, amphiphilic polymer polyphosphate mPEG- b-PHEP encapsulating the immune adjuvant R848, and nanoparticles doped with cationic liposomes DOTAP. Two nanomedicines were characterized and the efficacy of the nanovaccine was verified at the Cellular Experiments. At the animal level, the lymph node targeting of the nanoparticles was demonstrated through IVIS. We also constructed distant model and lung metastasis model to verify the nanovaccine's effect on enhancing systemic immunotherapy. Results: We used amphiphilic polymer polyphosphate mPEG- b-PHEP to encapsulate TLR7/8 agonist R848 to obtain VNP R848 nanoparticles. Gold nanorods (~ 100nm) can produce a strong photothermal effect mediated by NIR-II, killing tumor cells and releasing abundant antigens at the same time. The small size of VNPR848 (~ 30nm) is beneficial to the enrichment of lymph nodes. After capturing the antigens produced by photothermal, nanoparticles will be targeted and delivered to the tumor draining lymph nodes together with R848, and will be effectively absorbed by DC cells. This in situ tumor vaccine with the ability of targeted delivery of lymph nodes can trigger a strong anti-tumor immune response. This therapy can completely inhibit distant tumors in some mice and produce a long-term immune memory effect on NSCLC metastasis. Conclusions: We propose a simple personalized in situ cancervaccine strategy, which uses nanotechnology to remove tumors in situ and release antigens. Antigens and immune adjuvants are simultaneously delivered to the draining lymph nodes to initiate the antigen presentation function of DC cells, resulting in an anti-tumor immune response to inhibit tumor recurrence and metastasis. The nano-vaccine based on powerful therapeutic effect provides an attractive technology for in situ programming of personalized cancervaccine and an effective strategy for the development of cancervaccine.

NIR-II Probe Modified by Poly(l-Lysine) with Efficient Ovalbumin Delivery for Dendritic Cell Tracking

NIR-II Fluorescence Probe Based on Polyamidoamine Dendrimers for Immunotherapy as Antigen Carrier

A Novel TMTP1-modified Theranostic Nanoplatform for Targeted in Vivo NIR-II Fluorescence Imaging-guided Chemotherapy of Cervical Cancer

Conjugated Polymer Brush Based on Poly(l-lysine) with Efficient Ovalbumin Delivery for Dendritic Cell Vaccine.

Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.

Redox-responsive Hyperbranched Poly(amido Amine) and Polymer Dots As a Vaccine Delivery System for Cancer Immunotherapy

Ovalbumin-loaded Paramagnetic Nano-Triangles for Enhanced Dendritic Cell Stimulation, T1-MR Imaging, and Antitumor Immunity

Effect of NIR-II on cancer nanocomposite vaccines for lymph node targeted delivery and enhanced immunotherapy.

Two‐Pronged Intracellular Co‐Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

Shortwave-infrared-light-emitting probes for the in vivo tracking of cancer vaccines and the elicited immune responses

Antigen-Specific Stimulation of CD8+ T Cells by Murine Bone Marrow-Derived Dendritic Cells After Treatment with Nanoparticles

Near-infrared-II Responsive Ovalbumin Functionalized Gold-Genipin Nanosystem cascading photo-immunotherapy of cancer

NIR-II Fluorescent Molecular Bottlebrush Prepared by Ring-Opening Polymerization for Programmed Cell Death Ligand-1 Checkpoint Imaging

A Polymer Multicellular Nanoengager for Synergistic NIR‐II Photothermal Immunotherapy

Engineering ApoE3-incorporated Biomimetic Nanoparticle for Efficient Vaccine Delivery to Dendritic Cells Via Macropinocytosis to Enhance Cancer Immunotherapy

PEI-modified macrophage cell membrane-coated PLGA nanoparticles encapsulating Dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses

Gadolinium-doped Au@prussian blue nanoparticles as MR/SERS bimodal agents for dendritic cell activating and tracking

Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response